Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma

Abstract Background Despite major advances in therapy, multiple myeloma is still an incurable malignancy in the majority of patients. To increase survival, deeper remissions (i.e. CR) translating into longer PFS need to be achieved. Incorporation of new drugs (i.e. bortezomib and lenalidomide) as in...

Full description

Bibliographic Details
Main Authors: Hans Salwender, Uta Bertsch, Katja Weisel, Jan Duerig, Christina Kunz, Axel Benner, Igor W. Blau, Marc Steffen Raab, Jens Hillengass, Dirk Hose, Stefanie Huhn, Michael Hundemer, Mindaugas Andrulis, Anna Jauch, Andrea Seidel-Glaetzer, Hans-Walter Lindemann, Manfred Hensel, Stefan Fronhoffs, Uwe Martens, Timon Hansen, Mohammed Wattad, Ullrich Graeven, Markus Munder, Roland Fenk, Mathias Haenel, Christof Scheid, Hartmut Goldschmidt
Format: Article
Language:English
Published: BMC 2019-05-01
Series:BMC Cancer
Subjects:
Multiple myeloma
elotuzumab
autologous stem cell transplant
high-dose chemotherapy
Online Access:http://link.springer.com/article/10.1186/s12885-019-5600-x

Internet

http://link.springer.com/article/10.1186/s12885-019-5600-x

Similar Items